Lincus | Home

Next Generation Targeting of OncomiRs for Cancer Gene Therapy

Sponsor: American Cancer Society

Authors: Raman Bahal

2019-01-01 - 2022-12-31

Evaluation of LNPs for Pulmonary Delivery

Sponsor: Gatehouse Bio

Authors: Raman Bahal

2025-02-01 - 2025-07-30

Nanoparticles with chemically modified PNAs targeting multiple oncomiRs for brain tumor

Sponsor: DHHS/NIH/National Cancer Institute/Yale University

Authors: Raman Bahal

2025-07-01 - 2030-06-30

Next Generation Targeting of OncomiRs for Pediatric Glioma Therapy

Sponsor: Hood (Charles H.) Foundation

Authors: Raman Bahal

Funding: $165,000

2020-03-01 - 2022-08-31

Role of miR-33 in the metabolic basis of renal fibrogenesis

Sponsor: DHHS/NIH/National Institutes of Health/Yale University

Authors: Raman Bahal

2019-07-01 - 2024-06-30

Developing next generation synthetic nucleic acid analogous for sickle cell disease gene editing

Sponsor: DHHS/NIH/National Institutes of Health

Authors: Raman Bahal

2019-04-01 - 2024-03-31

Developing next generation nucleic acid analogues as a novel gene editing tool

Sponsor: DHHS/NIH/National Institutes of Health

Authors: Raman Bahal

2018-09-01 - 2023-08-31

Treatment of Lung Fibrosis by Pulmonary Delivery of Advanced Anti-miRs in Nanoparticles

Sponsor: DHHS/NIH/National Institutes of Health/Yale University

Authors: Raman Bahal

2024-09-01 - 2029-08-31

Nanoparticles with chemically modified PNAs targeting multiple oncomiRs for brain tumor

Sponsor: DHHS/NIH/National Institutes of Health/Yale University

Authors: Raman Bahal

2024-09-01 - 2029-08-31

Nanoparticles with chemically modified PNAs targeting multiple oncomiRs for brain tumor

Sponsor: DHHS/NIH/National Institutes of Health/Yale University

Authors: Raman Bahal

2024-04-01 - 2029-03-31

Anti-miR-33: A Novel Targeted Therapy for Pulmonary Fibrosis

Sponsor: DOD/Department of Defense/Yale University School of Medicine

Authors: Raman Bahal

2024-03-01 - 2027-02-28

Targeted delivery of next-generation anti-miRs for pulmonary fibrosis

Sponsor: DHHS/NIH/National Institutes of Health/Yale University

Authors: Raman Bahal

2024-04-01 - 2029-03-31

Sequence-specific inhibition of c-Myc in vivo by next-generation nucleic acid analogs

Sponsor: DHHS/NIH/National Institute of General Medical Sciences

Authors: Raman Bahal

2025-07-01 - 2030-06-30

Next-generation chemically modified PNAs for gene editing.

Sponsor: DHHS/NIH/National Institutes of Health/Yale University

Authors: Raman Bahal

2024-09-01 - 2029-08-31

Developing next-generation RNA inhibitors for stroke therapy

Sponsor: DHHS/NIH/National Institutes of Health/University of Connecticut Health Center

Authors: Raman Bahal

2024-09-01 - 2029-08-31

Next generation gamma Peptide Nucleic Acids (?PNAs) for the treatment of ischemic stroke

Sponsor: DHHS/NIH/National Institutes of Health/University of Connecticut Health Center

Authors: Raman Bahal

2019-09-01 - 2021-08-31

Gene editing therapy for Gaucher disease

Sponsor: DHHS/NIH/National Institutes of Health/Yale University

Authors: Raman Bahal

2021-04-01 - 2026-03-31

Targeted delivery of short antimiRs for lymphoma therapy

Sponsor: DHHS/NIH/National Cancer Institute

Authors: Raman Bahal

2020-07-01 - 2022-06-30

Intestinal Microbes, Beta-Cells miR-204, and Type 2 Diabetes

Sponsor: DHHS/NIH/National Institutes of Health/University of Iowa

Authors: Raman Bahal

2019-07-01 - 2024-06-30

Developing next-generation PNAs for selectively targeting the tumor microenvironment

Sponsor: Sigma Delta Epsilon Graduate Women in Science

Authors: Raman Bahal

2020-07-01 - 2021-06-30

Are you Raman Bahal?

How to update your information.